| Literature DB >> 33794820 |
Samantha Vanderslott1, Manya Van Ryneveld2, Mark Marchant3, Shelley Lees3, Sylvie Kwedi Nolna4, Vicki Marsh5,6,7.
Abstract
BACKGROUND: Community engagement (CE) is a well-established practical and scholarly field, recognised as core to the science and ethics of health research, for which researchers and practitioners have increasingly asked questions about desired standards and evaluation. In infectious disease outbreak contexts, questions may be more complex. However, it is unclear what body of knowledge has been developed for CE specifically as it applies to emerging infectious diseases. This scoping review seeks to describe (1) How CE has been conceptualised and understood; and (2) What conclusions have research teams reached on the effectiveness of CE in these settings, including challenges and facilitators.Entities:
Keywords: Community engagement; Effectiveness; Epidemics; Health research; Infectious disease; Outbreaks; Sub-Saharan Africa
Year: 2021 PMID: 33794820 PMCID: PMC8012744 DOI: 10.1186/s12889-021-10348-0
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Characteristics for data extraction
| Context descriptors | |
| Aims/objectives | |
| Research type/topic | |
| Community organisers | |
| Community organising actions and mechanisms of engagement | |
| Tools/medium | |
| Community target/definition | |
| Views on effectiveness/strengthening/quality/impact | |
| Experience, success and lessons/learnings | |
| Exiting |
Fig. 1PRISMA diagram
Trial name, intervention, targeted recruitment population, reported CE strategy, activities, and outcomes
| Trial Name | Intervention | Targeted recruitment population | Reported CE strategy | Reported CE activities and outcomes |
|---|---|---|---|---|
| STRIVE (completed) | Vaccine trial phase III; individually randomised, open-label trial; immediate vs deferred vaccination; 8673 participants enrolled. | Non-pregnant, frontline EVD health workers or related care workers across 5 districts in Sierra Leone. | Dedicated significant time and resources for CE. This meant communication beginning before trial launch (and presentation to the full government/ media). Communication continued post-enrolment to support ongoing recruitment and participation. | Communication activities included a 24-hour hotline for questions. Educational activities involved more than 175 sensitisation and information sessions for potential participants, hospitals, community health centres and ETUs. |
| Ebola ça Suffit (completed) | Ring vaccination; novel cluster RCT; immediate vs deferred vaccination; 7284 participants enrolled. | Index cases and their contacts within an epidemiologically informed ring. | Social mobilisation began prior to any vaccination related activities taking place. Consent was gained from the main ring site where the vaccination took place, around the index patient’s residence. | ‘Social mobilisation experts’ to find cases and contacts who they sought to mobilise and gain consent for participation. Community leaders and representatives assisted in contacting patients where applicable. The experts explained the trial’s objectives and implications of potential participation. |
| Ebovac Salone (ongoing) | Vaccine trial Phase III (staged). | Healthy volunteers, Sierra Leone. | Iterative CE approach strongly informed by prior and ongoing qualitative research. ‘Research-driven community engagement’ seen as contributing to smooth recruitment and reducing disruption due to rumours and misinformation. | Dedicated social science team and community liaison teams aimed to understand intra-community power dynamics. Conclusion that local understandings of fairness can inform the recruitment strategy design and rumours can be addressed through ‘active dialogue’ rather than on correcting misinformation. This emerging understanding was used to support and adapt CE over the course of the trial. |
| PREVAIL (completed) | Vaccine trial phase II/III; randomised, double-blind, placebo-controlled trial; 1500 participants enrolled. | Liberian residents aged > 18 years. High risk communities proximal and distal to an identified referral hospital in Monrovia. | Social mobilisation strategy with four pillars: advocacy, communications, community engagement and monitoring and evaluation. | Activities included: Reaching out to community decision-makers, opinion leaders and political leaders for support and approval, targeted messaging, answering FAQs, print and broadcast media communication, distributing flyers, jingles and songs on television and radio, text message communications with telecommunication companies’ subscribers etc. |
| JIKI (completed) | Treatment trial Phase II; non-comparative, single-arm, open-label clinical trial. | Any patient aged > 1 year with lab confirmed EVD; four rural Ebola treatment centers (ETCs) in Guinea. | The trial organisers recognised the context of fear and mistrust of international actors. The main recruitment efforts were inside the four ETCs involved in the study. A CAB was set up and involved in discussions on trial protocol, CE approach and informed consent processes. | A pretrial initiative was used to inform and involve community leaders, and develop ‘thoughtful, culturally appropriate messages’ and a consensual community strategy. The trial was conducted in partnership with public health response NGOs. |
| Ebola Tx. (completed) | Treatment trial, phase II/III. Open-label, nonrandomised clinical trial. | Donor mobilisation of EVD survivors. Lab-confirmed EVD patients | Strong focus on donor mobilisation and role of Survivors Association-motivation to donate linked to feelings of social responsibility as survivors. | Issues identified were the stigma and perceptions of health impacts of donating blood – a decrease in vital strength and antibodies, fears of loss of acquired protection against EVD. |
Stages of feedback loops. Based on article by [24]: p. 4
| 1. CE plans feedback | Social science team feedback to study team on CE plans based on socio-cultural research, local community dynamics and perceptions of the vaccine trial. |
| 2. Meetings to discuss issues | Brought up issues encountered by the trial team/ community liaison staff requiring further research by social science team (e.g. design of the recruitment strategies). |
| 3. Reporting rumours/ concerns | The social science team reported on rumours or concerns and communicated these to the community liaison team anonymously (not to breach confidentiality and to maintain independence of research). |
| 4. Response by community liaison staff | Following feedback, the community liaison staff brainstormed strategies to respond to concerns and rumours. Strategies depended on specific issues raised, but usually involved different creative avenues for discussion with community and reviewing messaging to actively engage, as well as determining who was the best person in the team to respond and through which channel. |
Literature divided by trials and three themes
| Ebola trials and trial-related | 1. Communication Towards Building Collaborative Relationships | 2. Producing contextual knowledge: Formative social science research | 3. Learning lessons over time: Incorporating findings, creating feedback loops and building a sustaining legacy |
|---|---|---|---|
Abramowitz et al. 2018 [ Alirol et al. 2017 [ Caleo et al. 2018 [ Coltart et al. 2017 [ Dean et al. 2016 [ Emanuel et al. 2004 Folayan et al. 2015 [ Keusch et al, 2017 [ Marsh et al, 2008 [ Marchant & Lees, 2019 [ Mehand et al. 2018 [ Mills et al. 2005 [ Olu et al. 2016 [ Pedi et al. 2017 [ Slevin et al. 2008 [ Tindana, 2007 [ UNAIDS, AVAC. 2011 [ Wellcome Trust and CIDRAP, 2015 [ WHO, 2017 [ WHO, 2016 [ Wilkinson et al. 2017 [ | Bedrosian et al. 2016 [ Browne et al. 2018 [ Callis et al. 2018 [ Carter et al. 2018 [ Ebola ça suffit consortium 2015 [ Emanuel et al. 2005 [ Enria et al. 2016 [ Enria et al. 2016a [ Enria et al. 2016b [ Fairhead 2016 [ Perez et al. 2017 [ Fayia Tengbeh et al. 2018 Fayia [ Kennedy et al. 2016 [ Mooney et al. 2018 [ Reynolds & Sariola 2018 [ Spengler et al. 2016 [ | CDC. 2013 [ Bonwitt et al. 2018 [ Delamou et al. 2016 [ Enria and Lees 2018 [ Enria et al. 2016 [ Fayia Tengbeh et al. 2018 Fayia [ Ronse et al. 2018 [ Johnson & Vinndrola-Padros, 2017 [ | Abayomi et al. 2016 [ Browne, et al. 2018 [ Callis et al. 2018 [ Delamou et al. 2016 [ Enria et al. 2016 [ Henao-Restrepo et al. 2016 [ Kennedy et al. 2016 [ Miller et al. 2018 [ Mooney et al. 2018 [ |